RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company focused on the development and commercialization of precision oncology therapies, today announced that its Chief Executive Officer, Shaun Bagai, will deliver a corporate presentation at the upcoming LD Micro Invitational XV: New York 2025 conference. The event will be held at the Westin Grand Central Hotel in New York, NY, on April 10, 2025.
The LD Micro Invitational is a prominent annual event bringing together institutional investors, analysts, family offices, and other members of the financial community to learn about emerging growth companies across a wide range of sectors, with a particular focus on small and micro-cap equities. RenovoRx’s participation in this year’s conference marks a timely opportunity for the company to share key corporate developments, product commercialization updates, and clinical progress with the broader investment community.
CEO Presentation to Highlight Commercial and Clinical Progress
During his presentation, Mr. Bagai will provide a comprehensive overview of RenovoRx’s recent achievements, highlighting significant advancements in both its commercial and clinical development programs. One of the key focal points will be the company’s continued progress in the market rollout of RenovoCath®, its innovative drug delivery system that has received clearance from the U.S. Food and Drug Administration (FDA). The device is designed to precisely deliver chemotherapeutic agents directly into targeted arteries feeding solid tumors, potentially increasing drug concentration at the tumor site while reducing systemic toxicity.
As part of his update, Mr. Bagai will outline RenovoRx’s commercial strategy, which has gained momentum in recent quarters. Specifically, the company has successfully secured multiple new purchase orders and reorders from leading cancer treatment centers across the United States. These sales reflect a growing confidence among clinicians in the utility and value of RenovoCath as a novel tool for regional drug delivery in oncology. The company has now begun to recognize its initial revenue from these sales, signaling a significant inflection point as it transitions from a purely development-stage company to a commercial-stage enterprise.
Overview of RenovoCath® and Its Market Potential
RenovoCath, the company’s flagship drug delivery system, is a core component of RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. TAMP is a targeted delivery approach that administers chemotherapeutic agents directly into arteries supplying the tumor, potentially optimizing drug uptake at the site of disease while minimizing systemic exposure. This platform is designed to address a critical challenge in cancer treatment—improving the therapeutic index of cytotoxic drugs, especially in hard-to-treat cancers.
Unlike conventional intravenous chemotherapy, which disperses drugs throughout the entire body, the TAMP platform enables localized drug perfusion. This approach has the potential to enhance efficacy, reduce treatment-related side effects, and improve patient outcomes. The RenovoCath device is central to this delivery methodology, and its FDA clearance validates its safety and technical performance, supporting its use in ongoing clinical trials and commercial settings.
Clinical Advancements: Phase III TIGeR-PaC Trial
A major component of RenovoRx’s pipeline is the TIGeR-PaC clinical trial—a pivotal Phase III study evaluating the efficacy and safety of the company’s lead drug-device combination product for the treatment of locally advanced pancreatic cancer (LAPC), a devastating and typically inoperable form of cancer with poor prognosis and limited therapeutic options.
The investigational product, referred to as IAG (Intra-Arterial Gemcitabine), combines the generic chemotherapy agent gemcitabine with targeted delivery via the RenovoCath catheter system. In this trial, IAG is being administered using the TAMP platform directly into the arterial blood supply of pancreatic tumors, aiming to maximize local drug concentration and improve survival outcomes.
Mr. Bagai’s presentation at LD Micro will include an in-depth discussion of the trial’s progress, including recent enrollment milestones, interim data, and future expectations. The TIGeR-PaC study is enrolling patients across a network of clinical trial sites in the U.S. and select international regions, reflecting strong investigator interest and institutional support.
If successful, this study could not only validate the therapeutic benefit of TAMP-based intra-arterial drug delivery in pancreatic cancer but also lay the foundation for expanding the platform to other solid tumors, including those affecting the liver, bladder, and biliary tract.
The Urgent Need for New Treatments in Pancreatic Cancer
Pancreatic cancer is among the most lethal forms of cancer, with a five-year survival rate of less than 11%, according to the American Cancer Society. Most patients are diagnosed at an advanced stage when surgical resection is not possible. Current treatment regimens are limited and often associated with significant side effects. New, more targeted approaches like RenovoRx’s TAMP platform are urgently needed to improve the quality of life and survival for these patients.
RenovoRx’s commitment to addressing this unmet need through innovation in localized drug delivery could represent a major breakthrough, particularly if the ongoing TIGeR-PaC trial demonstrates significant survival or quality-of-life benefits over standard systemic chemotherapy.
Positioning for Future Growth and Pipeline Expansion
Beyond the TIGeR-PaC trial, RenovoRx is actively exploring additional oncology indications where its TAMP platform could offer meaningful clinical advantages. The company is conducting preclinical research and feasibility assessments for applications in other cancers, aiming to build a diversified pipeline of drug-device combination therapies tailored for site-specific treatment.
In parallel, the company is pursuing strategic partnerships, grant funding, and collaborations to support its research and development initiatives. Mr. Bagai’s remarks at the LD Micro Invitational are expected to touch on these initiatives, along with ongoing discussions with potential commercial and academic partners.
A Transformative Year for RenovoRx
The upcoming LD Micro Invitational XV conference comes at a transformative moment for RenovoRx. As the company progresses from clinical development to commercial execution, it is establishing the infrastructure, relationships, and clinical evidence needed to support long-term success. With its first product now generating revenue and a pivotal clinical trial underway, RenovoRx is positioned to become a leader in precision oncology drug delivery.
Investors, healthcare professionals, and potential partners attending the LD Micro conference will have the opportunity to hear firsthand how RenovoRx is redefining the landscape of cancer treatment through innovation, execution, and a commitment to improving patient outcomes.
About RenovoRx, Inc.
RenovoRx is a biopharmaceutical company focused on developing and commercializing precision oncology therapies through localized drug delivery. The company’s Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to deliver chemotherapy directly to solid tumors via the arterial system, improving drug concentration at the tumor site while reducing systemic toxicity. RenovoRx’s lead product candidate, IAG (Intra-Arterial Gemcitabine), is currently being evaluated in the pivotal Phase III TIGeR-PaC clinical trial for the treatment of locally advanced pancreatic cancer. RenovoRx’s FDA-cleared delivery device, RenovoCath®, enables this targeted therapy and is also being commercially deployed across cancer centers in the United States.
